[{"orgOrder":0,"company":"Handa Pharmaceuticals","sponsor":"Nanocopoeia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Dasatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Handa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Handa Pharmaceuticals \/ Handa Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Handa Pharmaceuticals \/ Handa Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Handa Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Handa Therapeutics has acquired Phyrago (dasatinib) from Nanocopoeia. This FDA-approved product is indicated for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia.

                          Product Name : Phyrago

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 15, 2025

                          Lead Product(s) : Dasatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Nanocopoeia

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank